Shareholders Equity: The sum of preferred and common equity items.
Grace Therapeutics, Inc. (GRCE) had Shareholders Equity of $63.90M for the most recently reported fiscal year, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-7.79M |
|
-- |
|
-- |
|
$11.08M |
|
$-11.08M |
|
$1.58M |
|
$-9.49M |
|
$-9.49M |
|
$-7.79M |
|
$-7.79M |
|
$-7.79M |
|
$-7.79M |
|
$-11.08M |
|
$-11.07M |
|
16.51M |
|
16.51M |
|
$-0.47 |
|
$-0.47 |
|
| Balance Sheet Financials | |
$17.38M |
|
$0.01M |
|
$49.27M |
|
$66.65M |
|
$2.15M |
|
-- |
|
$0.61M |
|
$2.76M |
|
$63.90M |
|
$14.63M |
|
|
Shareholders Equity |
$63.90M |
16.02M |
|
| Cash Flow Statement Financials | |
$-8.87M |
|
-- |
|
$3.71M |
|
$22.13M |
|
$16.98M |
|
$-5.16M |
|
$0.80M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
8.10 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-8.87M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-12.20% |
|
-53.27% |
|
-11.69% |
|
-12.20% |
|
$3.99 |
|
$-0.54 |
|
$-0.54 |
|